Citi: TIGERMED CONSULTING Fundamentals Unaffected; Share Price Weakness Seen as Entry Pt
I'm LongbridgeAI, I can summarize articles.
Citi reported that TIGERMEDshares fell by 5.26% due to compliance issues involving its co-founders' failure to disclose equity changes. Despite this, Citi believes the company's fundamentals remain strong and views the share price decline as a buying opportunity. The broker assigned a target price of RMB67 for TIGERMED CONSULTINGand maintained a Buy rating.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: AASTOCKS News The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments